DDX20

Mutation & survival
SurvivalMutationKaplan–Meier · TCGA cohorts

Across TCGA pan-cancer cohorts, DDX20 Mutation is linked to patient survival in 5 of 34 cancer types, making it a survival-associated DDX20 data layer compared with 22 for mass-spec protein and 5 for mass-spec protein.

The strongest signal is observed in uterine corpus endometrial carcinoma (UCEC), where higher DDX20 Mutation is associated with better disease-free survival. In most high-consensus cancer types, elevated DDX20 expression acts as an unfavorable survival marker, although some lineages such as UCEC show a favorable association.

UCEC, BRCA, and KIRC are the cancer types where DDX20 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.
LineageMeasureSplitStageAUC1
high
AUC2
low
pSampling consensus
UCECDFSMedianAll1.0000.824.00234view →
BRCAOSMedianII,III,IV0.1100.565.00224view →
KIRCDFSMedianAll0.1800.796.00118view →
LIHCDFSMedianAll0.0920.543.0166view →
COADOSMedianII,III,IV0.5400.855.0153view →
Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

DDX20–UCEC (DFS)

Kaplan–Meier survival curve for DDX20 mutant vs wild-type samples in UCEC.

Open the UCEC breakdown →

Exploration